Search research articles
Contact Us
Filters
Showing results (21-30 of 160) with videos related to
Page
of 16
Sort By:
Frontiers in Microbiology
|
January 31, 2022
Corrigendum: A Systematic Study of the Stability, Safety, and Efficacy of the <i>de novo</i> Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against <i>Acinetobacter baumannii</i>
Sung-Pang Chen, Eric H-L Chen, Sheng-Yung Yang, et al.
Organic Letters
|
July 11, 2022
Metabolic Isolation, Stereochemical Determination, and Total Synthesis of Predominant Native Cholesteryl Phosphatidyl-α-glucoside from Carcinogenic <i>Helicobacter pylori</i>
Chia-Chen Chang, Hau-Ming Jan, Chieh-Jen Tseng, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 20, 2006
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan
Ming-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, et al.
World Journal of Gastroenterology
|
July 15, 2005
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin
Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Antiviral Research
|
July 30, 2005
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin
Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 6, 2025
A Point-of-Care Model for Hepatitis C Elimination in Remote Islands of Taiwan
Tzu-Chun Lin, Pei-Chien Tsai, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology
|
December 12, 2013
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection
Ching-I Huang, Chung-Feng Huang, Jee-Fu Huang, et al.
European Journal of Medicinal Chemistry
|
October 28, 2020
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease
Zheng-Sheng Lai, Teng-Kuang Yeh, Yu-Chi Chou, et al.
Hepatology International
|
February 3, 2011
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
Jeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, et al.
Journal of Hepatology
|
February 24, 2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients
Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.
Page
of 16
Search research articles
Search
Showing results (21-30 of 160) with videos related to
Sort By:
Page
of 16
Frontiers in Microbiology
|
January 31, 2022
Corrigendum: A Systematic Study of the Stability, Safety, and Efficacy of the <i>de novo</i> Designed Antimicrobial Peptide PepD2 and Its Modified Derivatives Against <i>Acinetobacter baumannii</i>
Sung-Pang Chen, Eric H-L Chen, Sheng-Yung Yang, et al.
Organic Letters
|
July 11, 2022
Metabolic Isolation, Stereochemical Determination, and Total Synthesis of Predominant Native Cholesteryl Phosphatidyl-α-glucoside from Carcinogenic <i>Helicobacter pylori</i>
Chia-Chen Chang, Hau-Ming Jan, Chieh-Jen Tseng, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 20, 2006
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan
Ming-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, et al.
World Journal of Gastroenterology
|
July 15, 2005
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin
Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Antiviral Research
|
July 30, 2005
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin
Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
The Kaohsiung Journal of Medical Sciences
|
June 6, 2025
A Point-of-Care Model for Hepatitis C Elimination in Remote Islands of Taiwan
Tzu-Chun Lin, Pei-Chien Tsai, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology
|
December 12, 2013
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection
Ching-I Huang, Chung-Feng Huang, Jee-Fu Huang, et al.
European Journal of Medicinal Chemistry
|
October 28, 2020
Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease
Zheng-Sheng Lai, Teng-Kuang Yeh, Yu-Chi Chou, et al.
Hepatology International
|
February 3, 2011
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan
Jeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, et al.
Journal of Hepatology
|
February 24, 2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients
Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.
Page
of 16